Literature DB >> 29881935

[Cannabinoids in pain medicine].

M Karst1.   

Abstract

The endocannabinoid system (ECS) controls a large number of vital functions. Suboptimal tone of the ECS in certain regions of the nervous system may be associated with disorders that are also associated with pain. Pain and inflammation processes can be modulated by the exogenous supply of cannabinoids. Low-to-moderate pain-relieving effects and in individual cases large pain-relieving effects were observed in randomized, controlled studies of various types of chronic pain. People with chronic neuropathic pain and stress symptoms seem to particularly benefit. The therapeutic range of cannabinoids is small; often small doses are sufficient for clinically significant effects. The "Cannabis-als-Medizin-Gesetz" (cannabis as medicine law) allows the prescription of cannabis preparations under certain conditions. Available data indicate good long-term efficacy and tolerability. However, there is little systematic long-term experience from clinical studies.

Entities:  

Keywords:  Cannabis based medication; Chronic pain; Endocannabinoid system; Neuropathic pain; “cannabis-as-medicine-law”

Mesh:

Substances:

Year:  2018        PMID: 29881935     DOI: 10.1007/s00482-018-0299-1

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  69 in total

1.  Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors.

Authors:  O Valverde; C Ledent; F Beslot; M Parmentier; B P Roques
Journal:  Eur J Neurosci       Date:  2000-02       Impact factor: 3.386

Review 2.  Cannabinoids, inflammation, and fibrosis.

Authors:  Robert B Zurier; Sumner H Burstein
Journal:  FASEB J       Date:  2016-07-19       Impact factor: 5.191

3.  Cannabinoid agonists attenuate capsaicin-induced responses in human skin.

Authors:  Roman Rukwied; Allan Watkinson; Francis McGlone; Melita Dvorak
Journal:  Pain       Date:  2003-04       Impact factor: 6.961

Review 4.  Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings.

Authors:  J Lötsch; I Weyer-Menkhoff; I Tegeder
Journal:  Eur J Pain       Date:  2017-11-21       Impact factor: 3.931

5.  Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep.

Authors:  Brian J Piper; Rebecca M DeKeuster; Monica L Beals; Catherine M Cobb; Corey A Burchman; Leah Perkinson; Shayne T Lynn; Stephanie D Nichols; Alexander T Abess
Journal:  J Psychopharmacol       Date:  2017-04-04       Impact factor: 4.153

Review 6.  Different contexts, different pains, different experiences.

Authors:  E Carlino; F Benedetti
Journal:  Neuroscience       Date:  2016-01-28       Impact factor: 3.590

7.  Amygdala activity contributes to the dissociative effect of cannabis on pain perception.

Authors:  Michael C Lee; Markus Ploner; Katja Wiech; Ulrike Bingel; Vishvarani Wanigasekera; Jonathan Brooks; David K Menon; Irene Tracey
Journal:  Pain       Date:  2013-01       Impact factor: 6.961

8.  The Impact of PTSD on Functioning in Patients Seeking Treatment for Chronic Pain and Validation of the Posttraumatic Diagnostic Scale.

Authors:  Sophia Åkerblom; Sean Perrin; Marcelo Rivano Fischer; Lance M McCracken
Journal:  Int J Behav Med       Date:  2017-04

9.  Psychiatric and physical comorbidities and pain in patients with multiple sclerosis.

Authors:  Rogier Scherder; Neeltje Kant; Evelien T Wolf; Bas Pijnenburg; Erik Ja Scherder
Journal:  J Pain Res       Date:  2018-02-13       Impact factor: 3.133

Review 10.  Endocannabinoid signaling in social functioning: an RDoC perspective.

Authors:  D S Karhson; A Y Hardan; K J Parker
Journal:  Transl Psychiatry       Date:  2016-09-27       Impact factor: 6.222

View more
  3 in total

Review 1.  [The use of cannabis-based drugs in pain and palliative medicine : Joint online questionnaire conducted by the Professional Association of Physicians and Psychotherapists in Pain and Palliative Medicine in Germany (BVSD), the German Pain Society, and the German Society for Pain Medicine (DGS)].

Authors:  Knud Gastmeier
Journal:  Schmerz       Date:  2019-10       Impact factor: 1.107

Review 2.  [Cannabis-based medicines for chronic pain: indications, selection of drugs, effectiveness and safety : Experiences of pain physicians in Saarland].

Authors:  Patric Bialas; Beate Drescher; Sven Gottschling; Stephanie Juckenhöfel; Dieter Konietzke; Wolfgang Kuntz; Isabell Kühne-Adler; Heidi Merl-Ripplinger; Diether Preisegger; Kathrein Schneider; Manfred Strauß; Patrick Welsch; Winfried Häuser
Journal:  Schmerz       Date:  2019-10       Impact factor: 1.107

3.  Efficacy, tolerability and safety of cannabis-based medicines for cancer pain : A systematic review with meta-analysis of randomised controlled trials.

Authors:  Winfried Häuser; Patrick Welsch; Petra Klose; Lukas Radbruch; Mary-Ann Fitzcharles
Journal:  Schmerz       Date:  2019-10       Impact factor: 1.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.